

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1999:421658 CAPLUS Full-text
 DN 131:58768
 TI Carboxylic acid substituted heterocycles as metalloproteinase inhibitors
 IN Koch, Kevin; Termin, Andreas; Josey, John A.
 PA Amgen Inc., USA
 SO PCT Int. Appl., 109 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9932452	A1	19990701	WO 1998-US27082	19981218
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6335329	B1	20020101	US 1998-213031	19981216
	CA 2315826	AA	19990701	CA 1998-2315826	19981218
	AU 9919325	A1	19990712	AU 1999-19325	19981218
	AU 746957	B2	20020509		
	EP 1042297	A1	20001011	EP 1998-964135	19981218
	EP 1042297	B1	20030226		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2001526267	T2	20011218	JP 2000-525389	19981218
	AT 233244	E	20030315	AT 1998-964135	19981218
	CN 1110482	B	20030604	CN 1998-813681	19981218
	ES 2191986	T3	20030916	ES 1998-964135	19981218
	US 6291450	B1	20010918	US 2000-588978	20000607
	US 2002065269	A1	20020530	US 2001-887479	20010622
	US 6593351	B2	20030715		
	US 2004029863	A1	20040212	US 2003-601975	20030623
PRAI	US 1997-68200P	P	19971219		
	US 1998-213031	A	19981216		
	WO 1998-US27082	W	19981218		
	US 2000-588978	A3	20000607		
	US 2001-887479	A3	20010622		
OS	MARPAT 131:58768				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The nitrogen heterocycle carboxylic acids I [m = 1, 2; n = 0, 1, 2; R1 = alkyl alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl substituted by HO, R3O, R3S, R3SO, NR3R4 (R3, R4 = H, alkyl, haloalkyl, aryl, etc.); R5, R6 = H, alkyl; R5R6 = bond; R9, R10 = A-B- (B = bond, (un)substituted alkyl, alkenyl, alkyl; A = H, halo, cyano, NO2, acyl, alkoxy carbonyl, carbamoyl, alkoxy, alkylamino, etc.); R11 = acyl, alkoxy carbonyl, carbamoyl, alkylsulfonyl, etc.; R33 = H, (un)substituted alkyl, heterocyclyl] and their pharmaceutically acceptable salts were

prepared as metalloproteinase inhibitors for prophylaxis and treatment of inflammation, tissue degradation, cancer, fibrosis and related diseases. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compns. and methods for prophylaxis and treatment of inflammation, tissue degradation and related diseases. The subject invention also relates to processes for making such compds. as well as to intermediates useful in such processes. Thus, D-aspartic acid β -benzyl ester underwent successive, esterification, methoxybenzenesulfonylation, and allylation reactions to give the allylsuccinate II which underwent metathesis/cyclization to give the azepinedicarboxylate III.


IT 228420-43-7P 228420-44-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of azepinedicarboxylates as metalloproteinase inhibitors)

RN 228420-43-7 CAPLUS

CN 2-Azocinecarboxylic acid, octahydro-1-[(4-methoxyphenyl)sulfonyl]-3-[[phenylmethyl)sulfonyl]amino]-, (2R,3S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 228420-44-8 CAPLUS

CN 2-Azocinecarboxylic acid, octahydro-1-[(4-methoxyphenyl)sulfonyl]-3-[[phenylmethyl)sulfonyl]amino]-, (2R,3R)-rel- (9CI) (CA INDEX NAME)



Relative stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 1 OF 5 MARPAT COPYRIGHT 2004 ACS on STN
 AN 139:276910 MARPAT Full-text
 TI Preparation of pyridinamine and pyrimidinamine derivatives as novel
 inhibitors of histone deacetylase
 IN Angibaud, Patrick Rene; Van Emelen, Kristof; Poncelet, Virginie Sophie;
 Roux, Bruno
 PA Janssen Pharmaceutica N.V., Belg.
 SO PCT Int. Appl., 63 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003076430	A1	20030918	WO 2003-EP2513	20030311
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2002-363799P		20020313		
GI					



AB The title compds. [I; n, m = 0-3; t = 0-1; Q, X, Y = N, C; Z = CH2, O;
 R1 = CONR3R4, NHCOR7, CO(alkanediyl)SR7, etc. (wherein R3, R4 = H, OH,
 alkyl, etc.; R7 = H, alkyl, alkylcarbonyl, etc.); R2 = H, OH, NH2, etc.;
 L = alkanediyl, CO, SO2, alkanediyl substituted with Ph; A =
 (un)substituted Ph, cyclohexyl, pyridyl, etc.], having histone
 deacetylase inhibiting enzymic activity, were prepared and formulated.
 E.g., a multi-step synthesis of II which showed pIC50 of 7.676 against
 HDAC, was given.

MSTR 1



G2 = (0-2) 17

HC—G4
17

G3 = 19

HC—G4
19

G4 = NH2 / 423

G(0)-G22
423

G17 = SO2

G22 = OH

MPL: claim 1

NTE: substitution is restricted

NTE: and N-oxides

NTE: also incorporates claim 10, structure II

NTE: additional substitution of rings in G18 also claimed

STE: and stereochemically isomeric forms

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 2 OF 5 MARPAT COPYRIGHT 2004 ACS on STN
 AN 139:189329 MARPAT Full-text
 TI Doped organic semiconductor material and method for production thereof
 IN Werner, Ansgar; Pfeiffer, Martin; Fritz, Torsten; Leo, Karl
 PA Novaled G.m.b.H., Germany
 SO PCT Int. Appl., 27 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003070822	A2	20030828	WO 2003-DE558	20030220
	WO 2003070822	A3	20040610		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR				
	DE 10207859	A1	20030904	DE 2002-10207859	20020220
	DE 10307125	A1	20040108	DE 2003-10307125	20030218

PRAI DE 2002-10207859 20020220

AB The invention relates to a doped organic semiconductor material with increased charge carrier d. and more effective charge carrier mobility, which may be obtained by doping an organic semiconductor material with a chemical compound comprising 1 or several organic mol. groups and at least one further compound partner. The desired doping effect is achieved after cleavage of at least one organic mol. group from the chemical compound by means of at least one organic mol. group or by means of the product of a reaction of at least one mol. group with another atom or mol. A method for production thereof is disclosed.

MSTR 11



G1 = NH2 (SO) / CO2H / SO3H

MPL: claim 26

NTE: additional ring and double bond formation also claimed

NTE: oxygens in G1 are free radicals

L8 ANSWER 3 OF 5 MARPAT COPYRIGHT 2004 ACS on STN
 AN 126:13050 MARPAT Full-text
 TI Electrophotographic migration imaging member
 IN Malhotra, Shadi L.; Chen, Liqin; Perron, Marie-Eve
 PA Xerox Corp., USA
 SO U.S., 144 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 5563014	A	19961008	US 1995-442227	19950515
	CA 2170298	AA	19961116	CA 1996-2170298	19960226
	CA 2170298	C	20011002		
	JP 08314241	A2	19961129	JP 1996-113457	19960508
	BR 9602246	A	19980113	BR 1996-2246	19960514
PRAI	US 1995-442227		19950515		

AB Disclosed is a migration imaging member comprising (a) a substrate, (b) a softenable layer comprising a softenable material and a photosensitive migration marking material, and (c) a transparentizing agent which transparentizes the migration marking material in contact therewith contained in at least one layer of the migration imaging member. Also disclosed is a process which comprises (1) providing a migration imaging member comprising (a) a substrate, (b) a softenable layer comprising a softenable material and a photosensitive migration marking material, and (c) a transparentizing agent which transparentizes the migration marking material in contact therewith contained in at least one layer of the migration imaging member, (2) uniformly charging the imaging member, (3) exposing the charged imaging member to an activating radiation at a wavelength to which the migration marking material is sensitive, and (4) causing the softenable material to soften and enabling a first portion of the migration marking material to migrate through the softenable material toward the substrate in an imagewise pattern while a second portion of the migration marking material remains substantially unmigrated within the softenable layer, wherein subsequent to migration of the first portion of migration marking material, either (a) the first portion of migration marking material contacts the transparentizing agent and the second portion of migration marking material does not contact the transparentizing agent or (b) the second portion of migration marking material contacts the transparentizing agent and the first portion of migration marking material does not contact the transparentizing agent.


MSTR 1

G2—G1


G1 = NH2 / 13



G2 = 26



G4 = SO2
G5 = OH
G6 = (0-3) 27



MPL: claim 11
NTE: additional ring formation and modification is allowed
NTE: also incorporates claims 15, 17, 20, 25 and 31

L8 ANSWER 4 OF 5 MARPAT COPYRIGHT 2004 ACS on STN
 AN 125:127644 MARPAT Full-text
 TI Method for obtaining improved image contrast in migration imaging members
 IN Limburg, William W.; Mammino, Joseph; Liebermann, George; Griffiths, Clifford H.; Shahin, Michael M.; Malhotra, Shadi L.; Chen, Liqin; Perron, Marie-Eve
 PA Xerox Corp., USA
 SO U.S., 147 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5514505	A	19960507	US 1995-441360	19950515
	CA 2169980	AA	19961116	CA 1996-2169980	19960221
	CA 2169980	C	20010424		
	JP 08314240	A2	19961129	JP 1996-113456	19960508
	EP 743573	A2	19961120	EP 1996-303359	19960514
	EP 743573	A3	19970305		
	EP 743573	B1	20000906		

R: DE, FR, GB


PRAI US 1995-441360 19950515

AB Disclosed is a process which comprises (a) providing a migration imaging member comprising (1) a substrate and (2) a softenable layer comprising a softenable material and a photosensitive migration marking material present in the softenable layer as a monolayer of particles situated at or near the surface of the softenable layer spaced from the substrate, (b) uniformly charging the imaging member, (c) imagewise exposing the charged imaging member to activating radiation at a wavelength to which the migration marking material is sensitive, (d) causing the softenable material to soften and enabling a first portion of the migration marking material to migrate through the softenable material toward the substrate in an imagewise pattern while a second portion of the migration marking material remains substantially unmigrated within the softenable layer, and (e) contacting the second portion of the migration marking material with a transparentizing agent which transparentizes the migration marking material.

MSTR 1



G1 = NH2 / 31 / SO3H



G2 = (1-3) 54



MPL: claim 10

L8 ANSWER 5 OF 5 MARPAT COPYRIGHT 2004 ACS on STN

AN 122:265358 MARPAT Full-text

TI Preparation of azabicyclic arthropodicides

IN Piotrowski, David Walter

PA du Pont de Nemours, E. I., and Co., USA

SO PCT Int. Appl., 59 pp.



CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9503306	A1	19950202	WO 1994-US8404	19940721
	W:	AM, AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KG, KP, KR, KZ, LK, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, US, UZ, VN			
	RW:	KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD,			
TG	AU 9474747	A1	19950220	AU 1994-74747	19940721
PRAI	US 1993-95876	19930722			
	US 1993-156197	19931122			
	WO 1994-US8404	19940721			
GI					




AB The title compds. [I; Q = (un)substituted azabicyclo group; R1, R2 = H, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, CN, SCN, NO2, (un)substituted NH2, etc.], useful as arthropodicides, are prepared and I-containing formulations presented. Thus, pyridine derivative II (m.p. 78-79°) was prepared and demonstrated mortality levels of ≥80% for two-spotted spider mites (*Tetranychus urticae*) on kidney bean leaves when applied at 0.5 kg/ha.

MSTR 1



G11 = 77




G12 = (0-2) CH2 (SO)

G20 = SO2

G25 = NO2 / CO2Me
MPL: claim 1
NTE: substitution is restricted

=> d l1; d his; log y
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

(FILE 'HOME' ENTERED AT 18:38:05 ON 01 JUL 2004)

FILE 'REGISTRY' ENTERED AT 18:38:15 ON 01 JUL 2004

L1 STRUCTURE UPLOADED
L2 0 S L1
L3 2 S L1 FUL

FILE 'CAPLUS' ENTERED AT 18:38:39 ON 01 JUL 2004

L4 1 S L3

FILE 'BEILSTEIN' ENTERED AT 18:39:01 ON 01 JUL 2004

L5 0 S L1 FUL

FILE 'MARPAT' ENTERED AT 18:39:14 ON 01 JUL 2004

L6 7 S L1 FUL
L7 6 S L6/COM
L8 5 S L7 NOT L4

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	132.09	293.24
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-3.30	-4.04

STN INTERNATIONAL LOGOFF AT 18:40:21 ON 01 JUL 2004